Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized controlled study assessing the effect of pre-emptive hyperventilation on ECT seizure duration, cerebral desaturation and remission of depressive symptoms in patients with Major Depressive Disorder. Comparison of etomidate and ketamine on remission of depressive symptoms with and without pre-emptive hyperventilation will also be studied.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Manitoba
• Treatments: Anesthetics; Etomidate; Ketamine

Criteria

Inclusion Criteria:

• Adults patients aged 18 to 85 years

• Diagnosed with Major Depressive Disorder, unipolar or bipolar depression

• Undergoing ECT for treatment of their symptoms

• Currently residing in Manitoba

Exclusion Criteria:

• Relative contraindications to ECT therapy (recent MI or CVA, increased intracranial pressure, intracranial mass lesion, intracranial aneurysm, epilepsy, known cardiac arrhythmia, pheochromocytoma, pregnancy)

• Contraindications to etomidate (sepsis, primary or secondary adrenal insufficiency, porphyria)

• DSM-V diagnosis of a lifetime history of psychotic spectrum disorder

• Drug or alcohol dependence, or abuse within the past 3 months, soy-bean oil allergy